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Abstract
BACKGROUND: Human immunodeficiency virus (HIV) and its therapy are
associated with increased aortic stiffness and metabolic syndrome (MetS)
phenotype in Caucasian patients. We hypothesized that, independently of
antiretroviral therapy, HIV infection in native black African patients is associated
with increased burden of cardiometabolic risk factors that may accelerate arterial
structural damage and translate into increased aortic stiffness. PATIENTS AND
METHODS: Ninety-six apparently healthy Cameroonian subjects (controls) were
compared to 108 untreated Cameroonian HIV+ patients (HIV-UT) of similar age.
In each participant, pulse wave velocity (Complior), aortic augmentation index
(SphygmoCor), brachial blood pressure (Omron 705 IT), fasting plasma glucose
(FPG), and lipids were recorded, as well as the prevalence and severity of
MetS, based on the American Heart Association/National Heart, Lung, and Blood
Institute score ≥3/5. RESULTS: Prevalence of impaired fasting glucose (FPG 1...
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Background: Human immunodeficiency virus (HIV) and its therapy are associated with 
increased aortic stiffness and metabolic syndrome (MetS) phenotype in Caucasian patients. 
We hypothesized that, independently of antiretroviral therapy, HIV infection in native black 
African patients is associated with increased burden of cardiometabolic risk factors that may 
accelerate arterial structural damage and translate into increased aortic stiffness.
Patients and methods: Ninety-six apparently healthy Cameroonian subjects (controls) were 
compared to 108 untreated Cameroonian HIV+ patients (HIV-UT) of similar age. In each par-
ticipant, pulse wave velocity (Complior), aortic augmentation index (SphygmoCor), brachial 
blood pressure (Omron 705 IT), fasting plasma glucose (FPG), and lipids were recorded, as 
well as the prevalence and severity of MetS, based on the American Heart Association/National 
Heart, Lung, and Blood Institute score $3/5.
Results: Prevalence of impaired fasting glucose (FPG 100–125 mg ⋅ dL-1) and of diabetes 
(FPG . 125 mg ⋅ dL-1) was higher in HIV-UT than in controls (47% versus 27%, and 26% versus 
1%, respectively; both P , 0.01). Fasting triglycerides and the atherogenic dyslipidemia ratio 
were significantly higher in HIV-UT than in controls. Hypertension prevalence was high and 
comparable in both groups (41% versus 44%, respectively; not significant). HIV-UT patients 
exhibited a twice-higher prevalence of MetS than controls (47% versus 21%; P = 0.02). Age- and 
sex-adjusted pulse wave velocity was higher in HIV-UT than in controls (7.5 ± 2.2 m/s versus 
6.9 ± 1.7 m/s, respectively; P = 0.02), whereas aortic augmentation index was significantly lower 
(6% ± 4% versus 8% ± 7%, respectively; P = 0.01).
Conclusion: Similar to Caucasian populations, native Cameroonian HIV-UT patients showed 
a higher prevalence of MetS and its phenotype, associated with increased aortic stiffness, an 
early marker of atherosclerosis.
Keywords: metabolic syndrome, HIV, arterial, stiffness, Cameroon
Introduction
Human immunodeficiency virus (HIV) infection and its therapy are associated with an 
increased risk of cardiovascular diseases (CVDs).1,2 The underlying pathophysiology 
has not yet been fully elucidated, but the virus appears to contribute directly to the 
accelerated development of arteriosclerosis.3 It may do this by increasing systemic 
inflammation, hypercoagulation, and platelet activation, leading to endothelial dysfunc-
tion.3–5 Independently of treatment, HIV infection has a direct effect on cholesterol and 
lipoproteins processing and transport, and may also increase cardiometabolic abnor-
malities, including visceral fat accumulation, diabetes, dyslipidemia, insulin resistance, 
and hypertension.3,6–10 All these abnormalities are either individual components of the 
metabolic syndrome (MetS) phenotype or of its underlying pathophysiology, and may 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
509
 O R I g I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/VHRM.S42350
Vascular Health and Risk Management  2013:9
predispose to the development of atherosclerosis; whereas 
westernized, unhealthy lifestyles and obesity are causally 
related to the acquisition of a MetS phenotype.
Increased arterial stiffness, assessed by aortic pulse 
wave velocity (PWV), is a direct marker of atherosclero-
sis and an independent predictor of cardiovascular (CV) 
outcomes,11 and PWV was reported to be more elevated in 
Caucasian untreated HIV-infected individuals than in healthy 
controls.12 Augmentation index (Aix), a direct measure of 
wave reflection and an aortic stiffness surrogate, is known 
to be an independent predictor of cardiovascular outcomes.13 
Despite the prevalence of HIV infection, the highest being in 
sub-Saharan Africa,14 the related cardiometabolic disorders 
and atherosclerosis risk has been poorly explored in native 
populations with HIV, as yet little exposed to westernized 
lifestyles. We therefore hypothesized that HIV infection 
in untreated black African patients, born and living in 
sub-Saharan Africa, is associated with increased burden 
of cardiometabolic risk factors that may accelerate arterial 
structural damage and translate into early-onset increased 
arterial stiffness.
Methods
The study design was cross-sectional and included 204 
volunteer subjects aged .18 years (55 males/149 females) 
recruited from the HIV clinic of Yaoundé Central Hospital, 
Cameroon, between September 2009 and May 2010. Two 
groups were analyzed in parallel: a group of 96 apparently 
healthy subjects (controls) was compared to a group of 108 
HIV-positive patients, untreated with antiretroviral drugs 
(HIV group), with similar mean age ± standard deviation 
(SD) (41 ± 12 years [controls] versus 39 ± 10 years [HIV]). 
Patients were included who had serologically documented 
HIV infection; and controls were apparently healthy subjects 
with recently documented (within the past year) seronegative 
status for HIV. Exclusion criteria for the two groups included: 
previously documented hypertension, diabetes, dyslipidemia; 
a history of cigarette smoking or regular alcohol consumption; 
current use of antidiabetics, antihypertensives, lipid-lowering 
drugs, or any others CV drugs; first-degree familial history 
of diabetes or early-onset coronary heart disease; and history 
of antiretroviral therapy (ART). Each volunteer provided a 
signed, informed consent, and the study was approved by the 
Institutional Review Board of the Yaoundé Central Hospital 
and Cameroonian Ministry of Public Health.
For each study participant, sociodemographic and clinical 
variables were recorded, including age, sex, and duration since 
HIV diagnosis (as a surrogate for HIV infection duration). 
All participants underwent a  physical examination by a single 
operator who measured the following parameters: weight, 
height, body mass index (BMI), waist circumference (as 
proxy for visceral fat), hip circumference, waist-to-height 
ratio, and conicity index ([waist circumference {m}/0.109] 
√[weight {kg}/height {m}]), the latter two being validated 
surrogates for central adiposity distribution. (Reference 
values for conicity index, from lean controls [n = 79] 
with normal glucose tolerance [NGT]: 1.22 ± 0.09 m2/kg 
[mean ± SD]; 1.16–1.26 m2/kg [interquartile range] and 1.03–
1.43 m2/kg [range]). Hypertension prevalence was defined as 
systolic blood pressure (BP) $140 mmHg and/or diastolic 
BP $90 mmHg.15 The presence of a MetS was defined by 
a score $3/5 for the following items: (1) impaired fasting 
glucose or diabetes; (2) hypertension; (3) enlarged waist; 
(4) elevated fasting triglycerides (TGs); (5) decreased high-
density lipoprotein cholesterol (HDL-C) (according to the 
International Diabetes Federation Task Force on Epidemiol-
ogy and Prevention; National Heart, Lung, and Blood Insti-
tute; American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International 
Association for the Study of Obesity harmonized definition), 
with the mean MetS score used as a surrogate for whole-body 
insulin resistance.16
Biochemical parameters
In all participants, a venous blood sample was collected after 
an overnight fast to measure the concentration of the following 
biochemical variables: fasting plasma glucose (FPG),  lipids 
(total cholesterol [C], HDL-C, TGs, LDL-C  [low-density 
lipoprotein C; computed from Friedewald’s formula]), and 
non-HDL-C (by subtracting HDL-C from total C). NGT, 
impaired fasting glucose, and diabetes were defined as FPG 
,100 mg ⋅ dL-1, 100–125 mg ⋅ dL-1, and .125 mg ⋅ dL-1, 
respectively. The prevalence of atherogenic dyslipidemia was 
defined as the combination of low HDL-C (,40 mg ⋅ dL-1 
[males] and ,50 mg ⋅ dL-1 [females]) plus high fasting TGs 
($150 mg ⋅ dL-1), whereas atherogenic  dyslipidemia severity, 
as a continuous variable, was determined by the log(TGs)/
HDL-C ratio (normal values for the latter, obtained from 79 
lean healthy subjects without familial histories for diabetes 
or early-onset cardiovascular disease: 0.036 [mean]; 0.012 
[SD]; 0.014 [minimum]; 0.067 [maximum]).17 Urinary Na+ 
and urinary K+ were determined from a spot urine sample. 
CD
4
+ cell counts (most recent value and nadir whenever 
possible) were recorded. All samples were analyzed at the 
central biochemical laboratory of ULB-Erasme Hospital, 
Brussels, Belgium.
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Hemodynamic measurements
To ensure a steady state, all hemodynamic measurements 
were performed in the morning after 15 minutes of supine 
rest in a quiet room. All participants were instructed to 
abstain from strong physical effort and from drinking caf-
feine, tea, or any alcoholic beverage for at least 2 hours 
before hemodynamic measurements. All measurements 
were performed by the same investigator in triplicate and 
averaged for analysis.
Brachial BPs and heart rate
Brachial systolic and diastolic BP and heart rate (HR) were 
recorded at the right arm with appropriate cuff size with the 
use of an automated sphygmomanometer (HEM-705 CP; 
Omron Corporation, Tokyo, Japan). Pulse pressure was cal-
culated as systolic minus diastolic BP, and mean arterial pres-
sure as diastolic BP plus one-third of pulse pressure value. 
All values were obtained from brachial measurements.
Carotid-femoral PWV
Carotid-femoral PWV was measured by the same investiga-
tor (DL) using sequential recordings of the arterial pressure 
waveform at the carotid and femoral arteries, with the use of 
a validated18 noninvasive device (Complior; Artech Medical, 
Pantin, France), which performs pressure wave recordings and 
automatically calculates PWV. The distance was defined as the 
distance from the suprasternal notch to femoral artery minus 
distance from carotid artery to the suprasternal notch. Pulse 
transit time was averaged over 10 consecutive beats. PWV 
corresponds to the ratio of the distance (meters) to the transit 
time (seconds). Intraobserver coefficient of variation for PWV 
for the same investigator (DL) was previously reported.19
Aortic augmentation index corrected  
for HR and BP
Aortic augmentation index corrected for HR (Aix), BP, and 
transit time was obtained from noninvasive pulse wave analy-
sis by means of radial applanation tonometry calibrated by 
the brachial BP (SphygmoCor version 6.1 software; AtCor 
Medical Pty Ltd, West Ryde, NSW, Australia), as described 
previously.19 The reproducibility of derived Aix has been vali-
dated previously.20 In our hands (DL), the mean ± SD intrao-
bserver within-session coefficient of variation for derived Aix 
measures using SphygmoCor was 7.1 ± 8.6 (n = 30).
Statistical methods
Data are presented as mean (± SD) or as proportion (%). 
The significance of differences between means was assessed 
by Student’s t-test or alternately by Welch’s t-test for data 
sets with significant differences in SD, and by Fisher’s 
exact test for differences in proportions, with TG values 
log-transformed prior to statistical analysis. A multiple 
regression analysis was performed to assess the indepen-
dent determinant of the PWV and Aix. All relevant vari-
ables that correlated with PWV and Aix at P , 0.01 were 
included in that model. Results were considered significant 
at P , 0.05.
Results
Patient characteristics
Sex distribution was not statistically different between con-
trol subjects and HIV patients. Men and women represented 
28% (n = 27) and 72% (n = 69) of the control group and 26% 
(n = 28) and 74% (n = 80) of the HIV group, respectively. 
Mean duration since HIV diagnosis was 19.3 (28.4) months. 
Height was comparable between groups, whereas weight was 
lower by an absolute mean of 10.5 kg in HIV (P , 0.01) 
compared with the controls, to such an extent that BMI was 
markedly lower in HIV patients than in controls (P = 0.02). 
Waist circumference was smaller by an average 9 cm in HIV 
patients than in controls (P , 0.01). Conicity index was 
comparable between groups, whereas the waist-to-height 
ratio, another surrogate for central adiposity, was lower in 
HIV patients (P , 0.01) (Table 1).
Table 2 describes the cardiometabolic phenotype of 
the two study groups. Based on FPG, the proportion of 
participants with NGT was higher in controls than in HIV 
patients (P , 0.01), whereas the prevalence of impaired 
fasting glucose and diabetes was markedly increased in 
HIV (both P , 0.05). Atherogenic dyslipidemia prevalence 
Table 1 Patients’ characteristics
Controls HIV P-value
n 96 108
Age (years) 41 ± 12 39 ± 11 0.21
Sex (%) (male, female) 28, 72 26, 74 0.75
Weight (kg) 75.3 ±15.4 64.8 ± 13.4 ,0.01
Height (m) 1.64 ± 0.09 1.63 ± 0.10 0.45
BMI (kg/m2) 28.1 ± 5.9 25.1 ± 12.1 0.02
BMI , 27.5 kg/m2 (%) 51 79 ,0.01
Waist circumference (cm) 90 ± 13 81 ± 10 ,0.01
Hip circumference (cm) 112 ± 26 106 ± 25 0.09
Waist-to-hip ratio 0.84 ± 0.22 0.80 ± 0.19 0.16
Conicity index (m2/kg) 1.24 ± 0.24 1.20 ± 0.18 0.17
Waist-to-height ratio 0.55 ± 0.09 0.50 ± 0.08 ,0.01
Note: Data are mean ± SD or proportions (%).
Abbreviations: HIV, untreated patients with human immunodeficiency virus; 
n, number; BMI, body mass index; SD, standard deviation.
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Table 2 Cardiometabolic phenotype
Controls HIV P-value
MetS (%) 21 47 0.02
MetS score (0/5 to 5/5) 1.7 ± 1.0 2.3 ± 1.1 ,0.01
Hyperglycemia 0.41 0.81 ,0.01
Enlarged waist 0.43 0.20 ,0.01
Elevated triglycerides 0.07 0.14 0.17
Low HDL-C 0.45 0.75 ,0.01
High blood pressure 0.34 0.40 0.46
Normal fasting glucose (%) 72 27 ,0.01
Impaired fasting glucose (%) 27 47 0.05
Diabetes (%) 1 26 ,0.01
Note: Data are mean (SD) or proportions (%), or scores (0/5 to 5/5 for MetS score, 
and 0/5 to 1/5 for the five individual components of the MetS).
Abbreviations: HIV, untreated patients with human immunodeficiency virus; MetS, 
metabolic syndrome; HDL-C, high-density lipoprotein cholesterol; SD, standard 
deviation.
Table 3 Laboratory values
Controls HIV P-value
Fasting plasma glucose  
(mmol ⋅ L-1)
5.2 ± 0.9 6.8 ± 3.2 ,0.01
Total cholesterol (mg ⋅ dL-1) 167 ± 43 151 ± 47 0.01
LDL-C (mg ⋅ dL-1) 103 ± 34 96 ± 39 0.17
Non-HDL-C (mg ⋅ dL-1) 118 ± 39 117 ± 39 0.85
HDL-C (mg ⋅ dL-1) 49 ± 17 34 ± 17 ,0.01
Total-C ⋅ HDL-C-1 4.11 ± 2.95 6.71 ± 6.98 ,0.01
Non-HDL-C ⋅ HDL-C-1 3.06 ± 2.96 5.71 ± 6.98 ,0.01
Tgs (mg ⋅ dL-1) 67 ± 35 155 ± 432 0.03
Log(Tgs) (mg ⋅ dL-1) 1.78 ± 0.19 1.94 ± 0.33 ,0.01
Tgs ,150 mg ⋅ dL-1 (%) 94 87 0.15
Log(Tgs) ⋅ HDL-C-1 0.048 ± 0.044 0.114 ± 0.169 0.02
Atherogenic dyslipidemia (%) 3 11 0.03
CD4
+ lymphocytes (× 106 ⋅ L-1) ∼ 353 ± 215 ∼
Urinary Na+ (mmol ⋅ L-1) 116 ± 59 91 ± 52 ,0.01
Urinary K+ (mmol ⋅ L-1) 74 ± 32 67 ± 33 0.12
Note: Data are mean (SD) or proportions (%).
Abbreviations: HIV, untreated patients with human immunodeficiency virus; 
C, cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; Tgs, triglycerides; Na+, sodium; K+, potassium; SD, standard 
deviation.
Table 4 Central and peripheral hemodynamics
Controls HIV P-value
Brachial SBP (mmHg) 128 ± 24 117 ± 20 ,0.01
Brachial DBP (mmHg) 83 ± 14 77 ± 13 ,0.01
Heart rate (bpm) 68 ± 11 78 ± 13 ,0.01
Mean arterial BP (mmHg) 98 ± 16 91 ± 15 ,0.01
Central SBP (mmHg) 118 ± 24 107 ± 19 ,0.01
Central DBP (mmHg) 84 ± 14 78 ± 13 ,0.01
PWV (m ⋅ s-1) 6.9 ± 1.7 7.5 ± 2.2 0.02
Aix (%) 8 ± 7 6 ± 4 ,0.01
Note: Data are mean (SD).
Abbreviations: HIV, untreated patients with human immunodeficiency virus; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minute; BP, 
blood pressure; PWV, pulse wave velocity; Aix, augmentation index (corrected for 
heart rate); SD, standard deviation.
was lower in controls than in HIV patients (P = 0.03). HIV 
patients exhibited a higher prevalence of MetS than controls 
(P = 0.02).
Laboratory values
Mean FPG was markedly higher in HIV than in controls 
(P , 0.01). Total cholesterol (C) was lower in HIV (P = 0.01), 
whereas LDL-C and non-HDL-C were comparable between 
groups. HDL-C was significantly lower, by an absolute mean 
of 7 mg ⋅ dL-1 in HIV (P , 0.01). The atherogenic ratios 
(total C/HDL-C) and (non-HDL-C/HDL-C), atherogenic 
dyslipidemia ratio (log[TGs]/HDL-C), and fasting TGs were 
significantly higher in HIV (all P , 0.05). Urinary Na+ excre-
tion was lower in HIV than in controls (P , 0.01), whereas 
urinary K+ did not differ between groups (Table 3).
Hemodynamic parameters
The prevalence of hypertension was high and comparable 
in both groups, despite the exclusion in the control group of 
participants with a known history of  hypertension. Brachial, 
central, and mean arterial BP were significantly higher in 
the control group (all P , 0.01). Heart rate was faster, by an 
absolute mean of 10 beats per minute (bpm), in HIV patients 
compared to controls (P , 0.01). Age- and sex-adjusted PWV 
was faster in HIV patients than in controls (P = 0.02), indicat-
ing increased arterial stiffness and predicting atherosclerosis 
risk in HIV patients (Table 4). There were no significant differ-
ences in mean arterial pressure, central systolic blood pressure 
(SBP), central diastolic blood pressure (DBP), central pulse 
pressure, PWV, or central pressure index between patients with 
shorter versus longer known duration of HIV infection.
Determinants of PWV and Aix
The relations between Aix, PWV, and cardiovascular vari-
able in the two groups are shown in Tables 5 and 6. Multiple 
regression analysis showed that LDL-C and age in the HIV 
group, and total cholesterol and fasting plasma glucose in 
the control group, were independent predictors of PWV 
(Table 7). Brachial SBP, brachial DBP, and age were inde-
pendent predictors of Aix in the HIV group, explaining 80% 
of variability; whereas male sex, brachial SBP, brachial DBP, 
and BMI were negatively and independently associated with 
Aix in the control group, accounting for 86% of the changes 
in Aix (Table 8).
Discussion
This study explored for the first time the impact of HIV infec-
tion on MetS, its phenotype components, and the association 
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Table 5 Relation between the augmentation index, aortic pulse 
wave velocity, and cardiovascular variable in the control group
Variables Aix PWV
r P-value r P-value
Age (years) 0.55 ,0.01 0.06 0.55
Weight (kg) 0.179 0.08 -0.027 0.79
Height (m) -0.382 ,0.01 -0.043 0.68
BMI (kg/m2) 0.42 ,0.01 0.02 0.84
Waist circumference (cm) 0.040 0.70 -0.018 0.86
Brachial SBP (mmHg) 0.496 ,0.01 0.024 0.81
Peripheral DBP (mmHg) 0.472 ,0.01 0.053 0.61
Heart rate (bpm)
Total C (mg ⋅ dL-1)
Tgs (mg ⋅ dL-1)
LDL-C (mg ⋅ dL-1)
HDL-C (mg ⋅ dL-1)
Fasting plasma glucose  
(mmol ⋅ l-1)
Urinary Na+ (mmol ⋅ L-1)
Urinary K+ (mmol ⋅ L-1)
Aix (%)
PWV (m ⋅ s-1)
0.129
0.026
-0.11
-0.39
0.031
-0.012
-0.54
0.286
0.78
0.20
0.8
0.93
0.76
0.81
0.911
0.65
0.01
0.45
0.06
0.38
0.167
0.353
0.211
0.009
-0.121
0.046
0.78
0.56
0.02
0.20
0.06
0.10
0.94
0.31
0.70
0.45
Abbreviations: Aix, augmentation index corrected for heart rate; PWV, pulse wave 
velocity; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; C, cholesterol; Tgs, triglycerides; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol; Na+, sodium; K+, potassium.
Table 6 Relation between augmentation index, aortic pulse wave 
velocity, and cardiovascular variable in the HIV group
Variables Aix PWV
r P-value r P-value
Age (years) 0.511 ,0.01 0.107 0.29
Weight (kg) 0.160 0.09 -0.094 0.35
Height (m) -0.192 0.05 -0.043 0.68
BMI (kg/m2) 0.281 ,0.01 0.02 0.84
Waist circumference (cm) 0.071 0.47 0.081 0.42
Brachial SBP (mmHg)
Brachial DBP (mmHg)
Heart rate (bpm)
Total C (mg ⋅ dL-1)
Tgs (mg ⋅ dL-1)
LDL-C (mg ⋅ dL-1)
HDL-C (mg ⋅ dL-1)
Fasting plasma glucose  
(mmol ⋅ L-1)
Urinary Na+ (mmol ⋅ L-1)
Urinary K+ (mmol ⋅ L-1)
Aix (%)
PWV (m ⋅ s-1)
0.460
0.281
-0.062
-0.047
0.069
-0.111
-0.054
0.100
 
-0.291
-0.228
0.011
,0.01
,0.01
0.52
0.64
0.5
0.28
0.60
0.31
 
0.04
0.02
0.91
0.053
0.078
-0.114
0.179
0.16
0.227
0.143
0.042
 
0.11
0.076
0.011
0.60
0.44
0.26
0.09
0.88
0.03
0.18
0.68
 
0.30
0.48
0.91
Abbreviations: Aix, augmentation index corrected for heart rate; PWV, pulse 
wave velocity; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; bpm, beats per minutes; C, cholesterol; Tgs, triglycerides; LDL-C, 
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; 
Na+, sodium; K+, potassium.
Table 7 Determinants of aortic PWV in multiple regression 
model
β P-value
HIV group
 LDL-C
 Age
0.02 ± 0.05
0.067 ± 0.023
,0.001
,0.0047
Controls group
 Total cholesterol
 Fasting plasma glucose
0.011 ± 0.005
0.025 ± 0.012
0.0455
0.0414
Notes: HIV group-included variables: LDL-C and age (R2 = 0.16; P , 0.05). Controls 
group-included variables: total cholesterol and fasting plasma glucose (R2 = 0.17; 
P , 0.05).
Abbreviations: PWV, pulse wave velocity; HIV, human immunodeficiency virus; 
LDL-C: low-density lipoprotein cholesterol.
Table 8 Determinants of Aix in multiple regression model
β P-value
HIV group
 Brachial SBP
 Brachial DBP
 Age
-0.47 ± 0.04
-1.32 ± 0.25
0.069 ± 0.01
,0.001
,0.001
,0.004
Controls group
 Male sex
 Brachial SBP
 Brachial DBP
 BMI
-2.82 ± 0.72
-0.50 ± 0.06
-2.25 ± 0.45
-0.12 ± 0.059
,0.001
,0.001
0.001
0.03
Notes: HIV group-included variables: brachial SBP, brachial DBP, and age (R2 = 0.80; 
P , 0.05). Controls group-included variables: male sex, brachial SBP, brachial DBP, 
and BMI (R2 = 0.86; P , 0.05).
Abbreviations: Aix, augmentation index (corrected for heart rate); HIV, human 
immunodeficiency virus; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
BMI, body mass index.
abnormalities, together with increased arterial stiffness 
assessed by PWV.
Only a handful of reports to date investigated HIV-
induced abnormalities in blood hemodynamics in native 
black autochthonous Africans. Lazar et al studied arterial 
wave reflection in untreated HIV+ Rwandan women and did 
not observe increased arterial stiffness in comparison with 
HIV- controls.21 Fourie et al reported an inflammatory injury 
pointing to endothelium dysfunction of never-treated HIV-1-
infected South Africans of African ancestry, but did not assess 
its association with the MetS or its components.22
Numerous studies suggested an increase of the burden 
of hypertension in the general population of sub-Saharan 
Africa.23,24 In the present study, the prevalence of hyperten-
sion was worryingly high, and comparable in the two groups. 
Fourie et al22 and Mufunda et al24 studied African untreated 
HIV patients and did not report increased BP compared with 
the general population, contrary to another report on HIV+ 
patients receiving ART.25 High dietary salt intake contributes 
to a substantial component of the rise in BP with age26 and 
is a major determinant of hypertension in black individu-
als.27 In the present study, the lower mean BP observed in 
with subclinical atherosclerosis among untreated black HIV+ 
natives living in sub-Saharan Africa. The major finding is 
that treatment-naïve Cameroonian HIV+ patients showed 
a high prevalence of MetS and related cardiometabolic 
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treatment-naïve Cameroonian HIV+ individuals could partly 
arise from lower dietary salt intake, because urinary Na+ 
excretion was significantly lower than that of controls.
Another original finding of the present study is the higher 
prevalence of dyslipidemia, with increased atherogenic ratios 
as well as atherogenic dyslipidemia, not previously docu-
mented in situ in untreated HIV+ black Africans.  Atherogenic 
dyslipidemia increases CV risk even when LDL-C is not 
elevated or controlled with statins.19 This finding may con-
tribute to increased atherosclerosis risk in HIV+ patients, 
long before ART is implemented, especially when elevated 
fasting TGs coincide with low HDL-C levels,28 as observed 
in this study.29,30 Even though sub-Saharan Africans have 
spontaneously lower triglyceridemia, our data are consistent 
with previous observations of similar lipid patterns, albeit 
more marked, in Caucasian HIV+ patients.9,12
Impaired glucose tolerance and diabetes are major comor-
bidities of CVD.31 Our study showed a higher prevalence 
of impaired fasting glucose in comparison with controls, at 
odds with previous studies in African treatment-naïve HIV 
patients.22,24 In Caucasian HIV+ individuals, glucose homeo-
stasis abnormalities were mostly ascribed to ART, especially 
when protease inhibitors were present.32
The MetS phenotype is closely related to insulin resis-
tance and compensatory hyperinsulinemia. The presence of 
a MetS, especially when its score is high (4/5 and 5/5), raises 
residual cardiovascular risk and is an established determinant 
of adverse cardiovascular outcomes.10,33 The MetS is more 
prevalent in the presence of HIV infection,9,10,34 as confirmed 
in the present study. Obesity is a major driver for the underly-
ing abnormalities of the MetS in the general population,33,35 as 
well as in HIV-infected individuals.9,10,25,34 In this latter popu-
lation, ART, particularly stavudine and protease inhibitors, 
directly contribute to impair insulin sensitivity.9,10,28 Other 
potential factors that may aggravate the MetS phenotype 
include acquired nonalcoholic steatohepatitis, hepatic insulin 
resistance and TG-rich particles overproduction associated 
with coinfection by hepatitis viruses. Serological data on 
hepatitis status in HIV patients were not available in the 
present study.
Despite lower indices for central adiposity and lack of 
ART use in the present study, HIV infection drastically 
increased the prevalence of the MetS and the severity of 
its score, the latter as a surrogate of whole-body insulin 
resistance. Our results suggest a possible influence of envi-
ronmental, sociocultural, and/or genetic factors, as well as 
HIV infection, on MetS expression. On the other hand, the 
prevalence of obesity and central adiposity, and the mean 
BMI and waist circumference, were lower in HIV individu-
als than in controls, in line with observations carried out 
in treatment-naïve HIV+ Caucasians.36,37 Fat redistribution 
and non-treatment-related acquired lipodystrophies are 
potential confounders in driving some of the discrepancies 
between global versus regional adiposity indices and MetS 
prevalence.
In the present study, treatment-naïve HIV+ patients had 
early-onset aortic stiffness, which corresponds to the early 
stage of subclinical atherosclerosis. Increased aortic stiffness 
is associated with cardiovascular risk factors and is an estab-
lished marker of early arterial pathology. Thus, alterations in 
arterial stiffness predate hypertension and are linked to car-
diovascular events in various settings.11–13 Increased arterial 
stiffness observed among untreated Cameroon HIV+ indi-
viduals was consistent with recent reports on treatment-naïve 
Caucasians.12,14 The high prevalence of atherogenic dyslipi-
demia observed in the present study may have contributed 
to increased arterial stiffness in HIV+ patients. Furthermore, 
HIV status by itself is associated with low-grade subclinical 
inflammatory injury of the endothelium, with endothelial 
dysfunction and accelerated atherosclerosis.4,22
The Aix, a surrogate measure of arterial stiffness, was 
unexpectedly lower in HIV+ patients. Our finding was in 
agreement with previous observations reported by Lazar 
et al21 in their investigation of arterial stiffness in HIV-
infected, never-treated Rwandan women. Although their 
study involved only women, our present study included both 
men and women with comparable magnitude between the 
two groups. Thus, the observed lower Aix cannot be attribut-
able to sex influence. Discrepancy between Aix and PWV 
was previously described in diabetic38 and elderly patients.39 
Carotid-femoral PWV is the gold standard measure of aortic 
stiffness, whereas Aix is a marker of reflected waves derived 
from pressure waveform. Aix is a composite measure that 
depends on PWV, reflection site, and reflected wave ampli-
tude. It may therefore appear unaltered in HIV-infected 
patients, in the setting of faster wave speed and reduced wave 
reflection, resulting from impedance mismatch at the point of 
reflection, due to peripheral vasodilatation.21 It seems likely 
that the effect of faster PWV observed in untreated HIV 
patients may have been attenuated, or probably overcome, by 
lesser central systolic augmentation in the aorta as a result 
of lower peripheral arterial resistances elicited by their lower 
brachial SBP.
Globally, the observed discrepancy as well as limited 
association between PWV and Aix in the present study dem-
onstrates that Aix is not a sensitive and reliable measure of 
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arterial stiffness in black African HIV-infected patients. Our 
finding complies with our previous observations reporting that 
Aix is not a surrogate of arterial stiffness during β-adrenergic 
stimulation by isoproterenol, compared with PWV, in both black 
African and  Caucasian  subjects.40 Furthermore, the validity of 
transfer function used in SphygmoCor to estimate central aor-
tic Aix in the Caucasian population is still debated and might 
introduce some degree of inaccuracy. Its normal range needs 
to be adapted and validated in black African subjects born and 
living in sub-Saharan Africa. Further research is required to 
consolidate our findings, to unravel the underlying mechanism, 
and to establish the role of peripheral arterial vasodilatation in 
the mechanism of wave reflections in HIV-infected patients.
This study highlights a series of potentially modifiable 
cardiovascular risk factors among sub-Saharan HIV-infected, 
never-treated African patients. This vulnerable population is at 
risk for both HIV-induced infectious diseases and HIV-related 
cardiometabolic outcomes, on top of sharing conventional risk 
factors for noncommunicable diseases otherwise increasingly 
prevalent in the general African population, such as high BP, 
sedentary lifestyle, food insecurity, excess caloric intake, 
and high saturated fat intake. Risk modification strategies, 
including screening, smoking avoidance, regular exercise, 
and therapeutic dietary changes may be especially effective if 
implemented early, when subclinical atherosclerosis develops, 
as reflected by early-onset aortic stiffness. This also means 
that, as elsewhere, clinicians should be particularly aware of 
considering the use of lipid-lowering drugs when needed, 
including fibrates for dyslipidemia, and to opt for antiretroviral 
agents with the lowest propensity to impair glucose homeo-
stasis, insulin sensitivity, or fat and lipids handling.41
The present study has several potential limitations, includ-
ing sample size, transversal design, use of surrogates markers 
for central fat assessment, definition of glucose homeostasis 
based on a single glucose measurement instead of repeat or 
postload assessment, and lack of laboratory measurement of 
subclinical inflammatory markers, such as high-sensitivity 
C-reactive protein, interleukin-6, vascular cell adhesion mol-
ecule-1, intercellular adhesion molecule-1, and plasminogen 
activator inhibitor-1. Further studies involving a larger popu-
lation with the assessment of these parameters are needed to 
confirm our findings. Because of funding and obvious logisti-
cal constraints, we recruited only at one center in Cameroon, 
and our results might therefore not be representative of other 
HIV+ patients from Cameroon or other sub-Saharan coun-
tries. However, the marked differences in cardiometabolic 
phenotype and PWV between patients and controls suggest 
that the conclusions of the present study are unlikely to be 
confounded only by these study limitations. Another study 
limitation is the predominance of the female sex in the studied 
population; it is increasingly recognized that the threshold 
value for pathological waist circumference currently used 
for black African populations may overpredict abdominal fat 
excess in women.42
Conclusion
In conclusion, HIV infection is associated with a high preva-
lence of MetS in treatment-naïve Cameroonian patients. The 
high frequency of atherogenic dyslipidemia, hypertension, 
and abnormal glucose homeostasis, together with increased 
frequency and severity of the metabolic syndrome in this 
population is associated with increased aortic PWV, an 
early marker of subclinical atherosclerosis. Because these 
acquired abnormalities are all modifiable by lifestyle or 
pharmacological interventions, these patients could benefit 
from preventive screening and targeted interventions to 
reduce their cardiometabolic risk.
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